Hers vs Shed: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher

48 providers verified independently·Independent research·How we rank →

Shed beats Hers overall, scoring 7.8/10 vs 7.3/10. Choose Hers for women who want brand-name wegovy (injection or pill) at $149. Choose Shed for users who want fast delivery and a streamlined compounded gl.

A side-by-side comparison of Hers and Shed covering pricing, scores, medication types, insurance, and more to help you decide.

Hers

#35 of 48

7.3/10

The women's health arm of Hims & Hers Health (NYSE: HIMS). In 2026 Hers signed a direct Novo Nordisk partnership adding FDA-approved Wegovy (pen and pill) at $149/mo and Zepbound via the Lilly partnership — alongside their existing compounded semaglutide and new compounded tirzepatide programs.

Visit Hers

Higher Rated

Shed

#17 of 48

7.8/10

Newer GLP-1 provider focused on speed and simplicity — fast approvals, fast shipping, and a clean user experience at a competitive price point.

Visit Shed

Feature	Hers	Shed
Our Score	7.3/10	7.8/10
Starting Price	$199/mo	$199/mo
Medication Type	Both	Both
Insurance Accepted	No	No
Best For	Women who want brand-name Wegovy (injection or pill) at $149/mo via the 2026 Novo Nordisk partnership, or a compounded semaglutide option from a publicly traded telehealth brand	Users who want fast delivery and a streamlined compounded GLP-1 experience
Ranking	#35	#17

Pros & Cons Compared

Hers

Pros

+2026 Novo Nordisk partnership — FDA-approved Wegovy pen and Wegovy oral pill from $149/mo, one of the lowest brand-name GLP-1 prices on the market
+Zepbound access via the Lilly/Hims-Hers partnership announced 2026
+Publicly traded company (NYSE: HIMS) with strong financial backing and regulatory compliance
+Broader women's health platform — integrates weight loss with hormonal, skin, and wellness services

Cons

−Membership + medication are billed separately ($39 first month / $149 ongoing membership) — watch the all-in math
−Generic support experience — large patient volume means less personalized attention
−Compounded pricing starts at $199/mo but stepped pricing applies at higher doses
−Zepbound access priced at ~$1,899/mo (brand cash) via the Lilly partnership — read as access, not value

Shed

Pros

+Industry-leading delivery speed — most patients receive medication within 2-3 days of enrollment
+$149/mo is competitively priced for an all-inclusive compounded program with good support
+Streamlined onboarding with no video call — approved and shipped faster than most competitors
+Clean, modern UX with real-time shipping tracking and easy provider messaging

Cons

−Compounded semaglutide and tirzepatide only — no brand-name options
−Newer company (founded 2024) with limited track record and outcome data
−No insurance billing and no FSA/HSA superbills currently available
−Clinical support is responsive but less proactive than premium platforms

Our Verdict

Shed edges out Hers with a score of 7.8/10 vs 7.3/10. Choose Hers if you want: women who want brand-name wegovy (injection or pill) at $149/mo via the 2026 novo nordisk partnership, or a compounded semaglutide option from a publicly traded telehealth brand. Choose Shed if you want: users who want fast delivery and a streamlined compounded glp-1 experience.

Still undecided? Editor's #1 Overall Pick

Embody

$299/mo · 7.3/10 · Compounded

If neither Hers nor Shed feels like the right fit, our overall #1 pick across all 48 GLP-1 telehealth providers is Embody — strongest balance of clinical oversight, transparent pricing, and verified availability.

Visit Embody→Read our full Embody review